{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-24-000064","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.537058+00:00","generated_at":"2026-05-31T12:26:10.629127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immuneering reports Q2 net loss $14.1M; Fast Track for IMM-1-104; initial Phase 2 data expected 2H 2024","bullets":["Net loss $14.1M ($0.47/share) vs $12.2M ($0.43) in Q2 2023.","Cash $59.7M as of June 30, 2024; expected cash runway into 2H 2025.","FDA granted Fast Track designation for IMM-1-104 in first-line pancreatic cancer.","Initial data from multiple arms of IMM-1-104 Phase 2a trial expected in 2H 2024.","Initial PK/PD/safety data for IMM-6-415 Phase 1 expected in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-24-000064","json":"https://secwatch.observer/filing/0001790340-24-000064.json","markdown":"https://secwatch.observer/filing/0001790340-24-000064.md","text":"https://secwatch.observer/filing/0001790340-24-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000064/0001790340-24-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000064/imrx-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:26:10.629127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}